While changes in both signalling pathways occurred in response to increased NFIB expression, their failure to parallel the phenotypic changes observed in the corresponding GBM cell subtypes suggests that neither pathway has as significant a role as p-STAT3 in determining NFIB-responsiveness. The gene discussed is NFIB; the disease is glioblastoma.